Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063181 | 0.94 | POLB (0.38) | CRHR1KMT2AALOX12LMNASMN1; SMN2 | |
| SCHEMBL3060845 | 0.73 | AR (0.32) | KMT2AALOX12LMNASMN1; SMN2MAPT | |
| SCHEMBL896318 | 0.72 | CNR2 (0.37) | CRHR1KMT2ARAB9AMAPTPOLB | |
| SCHEMBL10000761 | 0.71 | MAOB (0.40) | CRHR1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL3063136 | 0.71 | PDE2A (0.36) | KMT2ALMNASMN1; SMN2TP53MEN1 | |
| SCHEMBL3604528 | 0.69 | CNR2 (0.38) | CRHR1KMT2ARAB9AKDM4EALDH1A1 | |
| SCHEMBL3609800 | 0.69 | PTGS2 (0.43) | CRHR1 | |
| SCHEMBL10000738 | 0.69 | CNR2 (0.35) | CRHR1KMT2ASMN1; SMN2RAB9AKDM4E | |
| SCHEMBL3066117 | 0.69 | NPSR1 (0.41) | KMT2ALMNASMN1; SMN2RAB9AMAPT | |
| SCHEMBL3619780 | 0.68 | IDO1 (0.37) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-28 | — | — | US | claimed |
| EP-2220051-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | Syngenta Participations AG (CH) | 2010-08-25 | — | — | EP | claimed |
| WO-2009080314-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-02 | — | — | WO | claimed |
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA CROP PROTECTION, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2220051-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | Syngenta Participations AG (CH) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009080314-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273804-A1 | PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER | C3AR1, CBR3, C1S | CRHR1 2269/4885KMT2A 3241/4885ALOX12 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.